At the baseline visit, all inclusion and exclusion criteria will be re-assessed. Eligible patients will be randomized to treatment of the target area with either 30 minutes (group30) or 15 minutes (group15) blue light at 600 mW/cm². Additionally, two study areas with similar clinical symptomatology will be determined and will be randomized to blue light treated area and Daivonex treated area.